Faxed prescriptions will only be accepted from a prescriber. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to Senderra.

SENDERRA
Specialty Pharmacy

3712 E. Plano Parkway, Ste. 200
Plano, TX 75074

This prescription form is to be sent & received via fax

Dermatology Injectable Enrollment Form M - Z

Physician Offices Call: 855-460-7928

Fax: 888-777-5645

Prescriber:	**NPI:**
Supervising Physician:	**NPI:**
Address:	**Tax ID:**
Phone:	Fax:
Contact:	

PATIENT INFORMATION

Name:	☐ M ☐ F ☐ Trans M ☐ Trans F ☐ Other	DOB: ____/____/_____	SS#: ____-____-_____
Street:	City:	State:	ZIP:
Phone:	Alt. Phone:	☐ English ☐ Spanish ☐ Other: _____	Wt.: _____ Ht.: _____

PRESCRIPTION

Has the patient received a loading dose/starter kit? ☐**Yes Start Date:** ____/____/_____ ☐**No** | **SHIP TO:** ☐ **Patient's Home** ☐**Doctor's Office** ☐ **Other:**_____

Drug		Directions & Quantity	Refills
Siliq®	☐ Pre-filled Syringe	☐ **INITIAL:** Inject 210 mg SQ at weeks 0 & 1 (Quantity: 2) ☐ **MAINTENANCE:** Inject 210 mg SQ every 2 weeks starting at week 2 (Quantity: 2)	
Skyrizi®	☐Pen ☐Pre-filled Syringe	☐**INITIAL:** Inject 150 mg SQ at weeks 0 & 4 (Quantity: 1 plus 1 refill) ☐**MAINTENANCE:** Inject 150 mg SQ every 12 weeks (Quantity: 1)	
Stelara®	☐45 mg Pre-filled Syringe	☐**INITIAL:** Inject 45 mg SQ at weeks 0 & 4 (Quantity: 2) ***WEIGHT REQUIRED*** _____ ☐**MAINTENANCE:** Inject 45 mg SQ every 12 weeks (Quantity: 1) ***Intended for weight ≤ 100 kg/220 lbs***	
	☐90 mg Pre-filled Syringe	☐**INITIAL:** Inject 90 mg SQ at weeks 0 & 4 (Quantity: 2) ***Intended for weight > 100 kg/220 lbs*** ☐**MAINTENANCE:** Inject 90 mg SQ every 12 weeks (Quantity: 1)	
Taltz®	☐ Auto Injector ☐ Pre-filled Syringe	☐ **STARTING:** Inject 160 mg (2 x 80 mg) SQ at week 0, then begin first induction dose 80 mg (1 x 80 mg) 2 weeks later (week 2) (Quantity: 3) ☐ **INDUCTION:** Inject 80 mg SQ every 2 weeks (weeks 4-10) (Quantity: 2 plus 1 refill) ☐ **FINAL INDUCTION:** Inject 80 mg SQ (week 12) (Quantity: 1) ☐ **MAINTENANCE:** Inject 80 mg SQ every 4 weeks (thereafter) (Quantity: 1)	
Tremfya®	☐ One-Press Injector ☐ Pre-filled Syringe	☐ **INITIAL:** Inject 100 mg SQ at week 0 & 4 (Quantity: 2) ☐ **MAINTENANCE:** Inject 100 mg SQ every 8 weeks (Quantity: 1)	

MEDICAL INFORMATION

PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY

PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
☐ Methotrexate	☐ (_____)	☐	_____
☐ Soriatane	☐ (_____)	☐	_____
☐ Clobetasol	☐ (_____)	☐	_____
☐ Stelara	☐ (_____)	☐	_____
☐ Humira	☐ (_____)	☐	_____
☐ Enbrel	☐ (_____)	☐	_____
☐ _____	☐ (_____)	☐	_____
PHOTOTHERAPY	**Tried & Failed (Duration):**	**Not Tolerated:**	**Contraindication:**
☐ UVA /UVB	☐(_____)	☐	_____

☐Patient cannot afford ☐ Photosensitivity ☐Risk of Skin Cancer ☐ Distance from Office



Affected Areas

☐ Face ☐ Feet ☐ Groin ☐ Hands
☐ Nails ☐ Scalp ☐ Other:

BSA ____% PASI Score: ____

Date of Diagnosis: ____/____/_____

☐ L40.0 Psoriasis Vulgaris (Plaque Psoriasis) ☐ Other: _____

Allergies:

Active TB ruled out: ☐Yes ☐No Date: ___/___/____ Hep B ruled out/treated: ☐Yes ☐No Date: ___/___/____

Additional Clinical Information:

American Academy of Dermatology Consensus Statement on Psoriasis Therapies

☐Psoriasis is covering greater than 10% of body surface area ☐ Psoriasis is on palms, soles, head and neck, or genitalia ☐ Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints
☐Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment or interpersonal relationships

INJECTION TRAINING

☐Patient has received pen and injection training ☐ Physician's office to provide injection training ☐ Senderra to coordinate injection training

PRESCRIBER SIGNATURE

To Prescriber By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber: **Date**: ____/____/_____

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.